mesowatch
HomeImmunotherapy’s Power of Potential for Peritoneal Mesothelioma
divider

Promising Immunotherapy Case for Peritoneal Mesothelioma

immunotherapy attacking mesothelioma cancer cells

Frontiers in Oncology provisionally accepted a case report Friday suggesting the use of first-line nivolumab and ipilimumab could be more effective than chemotherapy in malignant peritoneal mesothelioma (MPM) treatment. 

A team of researchers working in France reported a 74-year-old woman with MPM had a “major and sustained 12-month response” to the anti-PD-1 nivolumab and the anti-CTLA 4 ipilimumab. 

“Our findings suggest a role for ICI in non-resectable diffuse MPM exhibiting PD-L1 overexpression and loss of BP1 expression, and install new hope in their treatment,” the report stated. 

The researchers believe this is only the second recorded case of a major clinical response to the use of dual immunotherapy as a treatment for malignant pleural mesothelioma. 

Types of Peritoneal Mesothelioma Treatment 

Mesothelioma, a form of cancer whose only known risk factor is asbestos exposure, usually originates in the lining of the lungs. This variant of the disease is called pleural mesothelioma. However, peritoneal mesothelioma affects the membrane around the digestive tract. The prognosis is poor for both these variants, but peritoneal mesothelioma is studied even less because it is so rare.

Peritoneal mesothelioma patients can undergo surgery to remove tumors. Although it has proven successful when combined with chemotherapy, the procedure is incredibly invasive. Sometimes the peritoneum must be removed. In some cases, parts of the structures that the peritoneum adheres to, such as the ovaries, uterus and gall bladder, and even parts of the intestines are removed.

Another treatment option is chemotherapy. It isn’t very effective by itself when used for mesothelioma patients, but it works better in combination with surgery and/or radiation treatments. 

Immunotherapy is the Next Wave of Treatment

Immunotherapy is a promising new frontier in mesothelioma treatment. Its goal is to stimulate the body’s immune system to destroy mesothelioma cancer cells. 

Some immunotherapy drugs target proteins that inhibit the body’s natural ability to fight cancer. Other drugs, such as nivolumab and ipilimumab, use antibodies instead. The FDA approved the use of those two medications in 2020 to treat some patients with malignant pleural mesothelioma who either didn’t respond to surgery or weren’t surgical candidates. 

A 2021 study showed an overall 23.5% survival rate in malignant pleural mesothelioma patients given nivolumab. However, research into how nivolumab might help those with peritoneal mesothelioma has lagged behind. That’s why the case report published Friday is a crucial next step in helping these patients live longer. 

Mary Pieper

Reading Time: 1 mins

Published On: July 5, 2024

Mary Pieper - author

Mary Pieper is a seasoned journalist, focusing on asbestos awareness and legal and medical issues. She earned her Bachelor's in English with a minor in Journalism from the University of Northern Iowa. Mary's extensive experience includes nearly 20 years as a reporter at the Globe Gazette in Mason City, Iowa, demonstrating her commitment to impactful journalism.

More to Read

Section Divider

Amna Anees - November 17, 2024

CHMP Recommends Pembrolizumab and Chemo for Pleural Mesothelioma

Mini Divider
Mesowatch Logo

Mesowatch serves as an industry watchdog and advocates for patients and families affected by asbestos by providing reliable and up-to-date news stories and information on asbestos and mesothelioma.

NAVIGATE

About UsEditorial GuidelinesNewsSupport and ResourcesPrivacy PolicySitemap

CONTACT US

Email: support@mesowatch.com

Phone: (866) 402-1000

Address: 3260 N Hayden Rd, Suite 210, Scottsdale, AZ 85251

Copyright © 2024 by Mesowatch. All Rights Reserved.
At Mesowatch, we strive to provide helpful information for your journey. Please remember that the content on our website is for informational purposes only and is protected by copyright law. It is not a substitute for professional medical or legal advice. We encourage you to consult qualified professionals for any health or legal concerns. Disclaimer